{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:21:28Z","timestamp":1788344488939,"version":"build-2803163510"},"reference-count":82,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Group 3 pulmonary hypertension is a common and clinically significant complication of chronic lung disease and hypoxia that is associated with impaired functional capacity, right ventricular dysfunction, and increased mortality. Historically viewed as a consequence of underlying parenchymal lung disease, Group 3 pulmonary hypertension is now recognized as a complex disorder involving pulmonary vascular remodeling, dysregulated molecular signaling, and maladaptive cardiopulmonary interactions. Advances in translational research have improved our understanding of the mechanisms driving disease progression and have informed the development of targeted therapeutic strategies. This review provides an overview of the current understanding of Group 3 pulmonary hypertension, including its pathophysiology, diagnostic evaluation, and evolving treatment landscape. Specifically, this review dives into the reason behind limited therapeutic success, the outcomes of previous clinical trials, and the emergence of lung-selective approaches that seek to balance pulmonary vascular benefit with preservation of gas exchange. Collectively, these developments highlight both the progress made and the ongoing need for improved phenotyping and novel therapeutic approaches in the Group 3 pulmonary hypertension patient population.<\/jats:p>","DOI":"10.3390\/jcm15176810","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:02:52Z","timestamp":1788343372000},"page":"6810","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Group 3 Pulmonary Hypertension: Mechanistic Insights, Clinical Challenges, and Evolving Therapies"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9025-5629","authenticated-orcid":false,"given":"Steven C.","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Parkview Health, 11109 Parkview Plaza Dr., Fort Wayne, IN 46845, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Ku","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Parkview Health, 11109 Parkview Plaza Dr., Fort Wayne, IN 46845, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Mohnani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Parkview Health, 11109 Parkview Plaza Dr., Fort Wayne, IN 46845, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanvi","family":"Borse","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Parkview Health, 11109 Parkview Plaza Dr., Fort Wayne, IN 46845, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Bajantri","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Critical Care Medicine, Parkview Health, 11109 Parkview Plaza Dr., Fort Wayne, IN 46845, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension: Developed by the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on Rare Respiratory Diseases (ERN-LUNG)","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1801914","DOI":"10.1183\/13993003.01914-2018","article-title":"Pulmonary Hypertension in Chronic Lung Disease and Hypoxia","volume":"53","author":"Nathan","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease","volume":"384","author":"Waxman","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.chest.2025.07.4107","article-title":"Pulmonary Hypertension Associated With Interstitial Lung Diseases","volume":"169","author":"Jose","year":"2026","journal-title":"Chest"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/jama.2022.4402","article-title":"Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review","volume":"327","author":"Ruopp","year":"2022","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e70005","DOI":"10.1002\/pul2.70005","article-title":"Screening and Diagnosis of Pulmonary Hypertension Associated with Chronic Lung Disease (PH-CLD): A Consensus Statement from the Pulmonary Vascular Research Institute\u2019s Innovative Drug Development Initiative\u2014Group 3 Pulmonary Hypertension","volume":"14","author":"Vitulo","year":"2024","journal-title":"Pulm. Circ."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1161\/CIRCRESAHA.121.319970","article-title":"Group 3 Pulmonary Hypertension: From Bench to Bedside","volume":"130","author":"Singh","year":"2022","journal-title":"Circ. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.1172\/JCI137558","article-title":"Hypoxia-Inducible Factor Signaling in Pulmonary Hypertension","volume":"130","author":"Pullamsetti","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1152\/physrev.00030.2011","article-title":"Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2","volume":"92","author":"Prabhakar","year":"2012","journal-title":"Physiol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"15652","DOI":"10.1074\/jbc.M608318200","article-title":"Hypoxia-Inducible Expression of a Natural Cis-Antisense Transcript Inhibits Endothelial Nitric-Oxide Synthase","volume":"282","author":"Fish","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.2174\/138955709788922610","article-title":"HIF-1alpha Modulates Energy Metabolism in Cancer Cells by Inducing over-Expression of Specific Glycolytic Isoforms","volume":"9","author":"Ralph","year":"2009","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1091\/mbc.e09-12-1003","article-title":"The NADPH Oxidase Subunit NOX4 Is a New Target Gene of the Hypoxia-Inducible Factor-1","volume":"21","author":"Diebold","year":"2010","journal-title":"Mol. Biol. Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.freeradbiomed.2004.02.071","article-title":"Upregulation of NAD(P)H Oxidase 1 in Hypoxia Activates Hypoxia-Inducible Factor 1 via Increase in Reactive Oxygen Species","volume":"36","author":"Goyal","year":"2004","journal-title":"Free Radic. Biol. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1183\/13993003.00945-2015","article-title":"Oxygen Sensing and Signal Transduction in Hypoxic Pulmonary Vasoconstriction","volume":"47","author":"Sommer","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.chest.2016.09.001","article-title":"Hypoxic Pulmonary Vasoconstriction: From Molecular Mechanisms to Medicine","volume":"151","author":"Wu","year":"2017","journal-title":"Chest"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Poyatos, P., Gratac\u00f3s, M., Samuel, K., Orriols, R., and Tura-Ceide, O. (2023). Oxidative Stress and Antioxidant Therapy in Pulmonary Hypertension. Antioxidants, 12.","DOI":"10.3390\/antiox12051006"},{"key":"ref_17","first-page":"L256","article-title":"Endothelial HIF-2\u03b1 Contributes to Severe Pulmonary Hypertension Due to Endothelial-to-Mesenchymal Transition","volume":"314","author":"Tang","year":"2018","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Hu, C.-J., Poth, J.M., Zhang, H., Flockton, A., Laux, A., Kumar, S., McKeon, B., Mouradian, G., Li, M., and Riddle, S. (2019). Suppression of HIF2 Signalling Attenuates the Initiation of Hypoxia-Induced Pulmonary Hypertension. Eur. Respir. J., 54.","DOI":"10.1183\/13993003.00378-2019"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1165\/rcmb.2014-0045TR","article-title":"The Role of Vascular Endothelial Growth Factor in Pulmonary Arterial Hypertension. The Angiogenesis Paradox","volume":"51","author":"Voelkel","year":"2014","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1161\/CIRCULATIONAHA.123.067005","article-title":"ErbB3 Governs Endothelial Dysfunction in Hypoxia-Induced Pulmonary Hypertension","volume":"150","author":"Bian","year":"2024","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"308ra159","DOI":"10.1126\/scitranslmed.aaa9712","article-title":"Smooth Muscle Cell Progenitors Are Primed to Muscularize in Pulmonary Hypertension","volume":"7","author":"Sheikh","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_22","first-page":"855","article-title":"Hypoxia Promotes Pulmonary Vascular Remodeling via HIF-1\u03b1 to Regulate Mitochondrial Dynamics","volume":"16","author":"Chen","year":"2019","journal-title":"J. Geriatr. Cardiol. JGC"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1096\/fj.05-4104fje","article-title":"Impact of HIF-1\u03b1 and HIF-2\u03b1 on Proliferation and Migration of Human Pulmonary Artery Fibroblasts in Hypoxia","volume":"20","author":"Eul","year":"2006","journal-title":"FASEB J."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Philip, J.L., Caneba, C.A., Caggiano, L.R., Prakash, N., Cheng, T.-C., Barlow, K.A., Mustafa, T., Tabima, D.M., Hacker, T.A., and Masters, K.S. (2025). Hypoxia Modulates Human Pulmonary Arterial Adventitial Fibroblast Phenotype through HIF-1\u03b1 Activation. bioRxiv, 2025.01.27.635152.","DOI":"10.1101\/2025.01.27.635152"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4049\/jimmunol.165.2.1013","article-title":"Role of Oxidants in NF-Kappa B Activation and TNF-Alpha Gene Transcription Induced by Hypoxia and Endotoxin","volume":"165","author":"Chandel","year":"2000","journal-title":"J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5106","DOI":"10.1128\/MCB.00060-08","article-title":"Reactive Oxygen Species Regulate Hypoxia-Inducible Factor 1alpha Differentially in Cancer and Ischemia","volume":"28","author":"Qutub","year":"2008","journal-title":"Mol. Cell. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e17167","DOI":"10.1016\/j.heliyon.2023.e17167","article-title":"Hypoxia Inducible Factor-1\u03b1 Is an Important Regulator of Macrophage Biology","volume":"9","author":"Qiu","year":"2023","journal-title":"Heliyon"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1164\/ajrccm.164.4.2101023","article-title":"Reduced Expression of Endothelial Nitric Oxide Synthase in Pulmonary Arteries of Smokers","volume":"164","author":"Peinado","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1183\/09031936.02.00245902","article-title":"Characterization of Pulmonary Vascular Remodelling in Smokers and Patients with Mild COPD","volume":"19","author":"Santos","year":"2002","journal-title":"Eur. Respir. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1164\/ajrccm.159.5.9807059","article-title":"Inflammatory Reaction in Pulmonary Muscular Arteries of Patients with Mild Chronic Obstructive Pulmonary Disease","volume":"159","author":"Peinado","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1165\/rcmb.2020-0008OC","article-title":"Mitochondrial Fission Mediated Cigarette Smoke\u2013Induced Pulmonary Endothelial Injury","volume":"63","author":"Wang","year":"2020","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1164\/rccm.200210-1233OC","article-title":"Enhanced Expression of Vascular Endothelial Growth Factor in Pulmonary Arteries of Smokers and Patients with Moderate Chronic Obstructive Pulmonary Disease","volume":"167","author":"Santos","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/303059","article-title":"Familial Primary Pulmonary Hypertension (Gene PPH1) Is Caused by Mutations in the Bone Morphogenetic Protein Receptor-II Gene","volume":"67","author":"Deng","year":"2000","journal-title":"Am. J. Hum. Genet."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"International PPH Consortium, Lane, K.B., Machado, R.D., Pauciulo, M.W., Thomson, J.R., Phillips, J.A., Loyd, J.E., Nichols, W.C., and Trembath, R.C. (2000). Heterozygous Germline Mutations in BMPR2, Encoding a TGF-Beta Receptor, Cause Familial Primary Pulmonary Hypertension. Nat. Genet., 26, 81\u201384.","DOI":"10.1038\/79226"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S2213-2600(15)00544-5","article-title":"BMPR2 Mutations and Survival in Pulmonary Arterial Hypertension: An Individual Participant Data Meta-Analysis","volume":"4","author":"Evans","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Rol, N., Kurakula, K.B., Happ\u00e9, C., Bogaard, H.J., and Goumans, M.-J. (2018). TGF-\u03b2 and BMPR2 Signaling in PAH: Two Black Sheep in One Family. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19092585"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1165\/rcmb.2012-0470OC","article-title":"Transforming Growth Factor-B1 Represses Bone Morphogenetic Protein\u2013Mediated Smad Signaling in Pulmonary Artery Smooth Muscle Cells via Smad3","volume":"49","author":"Upton","year":"2013","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/cr.2007.67","article-title":"Beginning to Understand microRNA Function","volume":"17","author":"Du","year":"2007","journal-title":"Cell Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1172\/JCI10259","article-title":"Inhibition of VEGF Receptors Causes Lung Cell Apoptosis and Emphysema","volume":"106","author":"Kasahara","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/ame2.12220","article-title":"Experimental Animal Models of Pulmonary Hypertension: Development and Challenges","volume":"5","author":"Wu","year":"2022","journal-title":"Anim. Models Exp. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e12213","DOI":"10.1002\/pul2.12213","article-title":"Pathogenesis, Clinical Features, and Phenotypes of Pulmonary Hypertension Associated with Interstitial Lung Disease: A Consensus Statement from the Pulmonary Vascular Research Institute\u2019s Innovative Drug Development Initiative\u2013Group 3 Pulmonary Hypertension","volume":"13","author":"Piccari","year":"2023","journal-title":"Pulm. Circ."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2353\/ajpath.2010.090832","article-title":"Hypoxia Inducible-Factor1\u03b1 Regulates the Metabolic Shift of Pulmonary Hypertensive Endothelial Cells","volume":"176","author":"Fijalkowska","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1164\/rccm.201806-1160ST","article-title":"Assessment of Right Ventricular Function in the Research Setting: Knowledge Gaps and Pathways Forward. An Official American Thoracic Society Research Statement","volume":"198","author":"Lahm","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jacc.2016.10.047","article-title":"The Relationship Between the Right Ventricle and Its Load in Pulmonary Hypertension","volume":"69","author":"Westerhof","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1801900","DOI":"10.1183\/13993003.01900-2018","article-title":"Pathophysiology of the Right Ventricle and of the Pulmonary Circulation in Pulmonary Hypertension: An Update","volume":"53","author":"Chin","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCRESAHA.113.301129","article-title":"The Right Ventricle in Pulmonary Arterial Hypertension: Disorders of Metabolism, Angiogenesis and Adrenergic Signaling in Right Ventricular Failure","volume":"115","author":"Ryan","year":"2014","journal-title":"Circ. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1161\/CIRCRESAHA.115.301130","article-title":"The Metabolic Theory of Pulmonary Arterial Hypertension","volume":"115","author":"Paulin","year":"2014","journal-title":"Circ. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00109-009-0524-6","article-title":"The Inhibition of Pyruvate Dehydrogenase Kinase Improves Impaired Cardiac Function and Electrical Remodeling in Two Models of Right Ventricular Hypertrophy: Resuscitating the Hibernating Right Ventricle","volume":"88","author":"Piao","year":"2010","journal-title":"J. Mol. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1378\/chest.11-0615","article-title":"Obstructive Sleep Apnea: Effects of Continuous Positive Airway Pressure on Cardiac Remodeling as Assessed by Cardiac Biomarkers, Echocardiography, and Cardiac MRI","volume":"141","author":"Colish","year":"2012","journal-title":"CHEST"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"E38","DOI":"10.1111\/j.1399-0012.2010.01318.x","article-title":"The Effects of Bilateral Lung Transplantation on Ventilatory Efficiency, Oxygen Uptake and the Right Heart: A Two-Yr Follow-Up","volume":"25","author":"Habedank","year":"2011","journal-title":"Clin. Transplant."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1513\/AnnalsATS.201509-599FR","article-title":"The Critical Role of Pulmonary Arterial Compliance in Pulmonary Hypertension","volume":"13","author":"Thenappan","year":"2016","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1161\/CIRCULATIONAHA.106.632208","article-title":"Right Ventricular Function and Failure: Report of a National Heart, Lung, and Blood Institute Working Group on Cellular and Molecular Mechanisms of Right Heart Failure","volume":"114","author":"Voelkel","year":"2006","journal-title":"Circulation"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"00272","DOI":"10.1183\/23120541.00272-2022","article-title":"Pulmonary Hypertension in Interstitial Lung Disease: An Area of Unmet Clinical Need","volume":"8","author":"Dhont","year":"2022","journal-title":"ERJ Open Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.chest.2018.11.030","article-title":"Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report","volume":"155","author":"Klinger","year":"2019","journal-title":"Chest"},{"key":"ref_55","first-page":"S2","article-title":"Shining a Spotlight on Pulmonary Hypertension Associated with Interstitial Lung Disease Care: The Latest Advances in Diagnosis and Treatment","volume":"31","author":"Nathan","year":"2025","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Haynes, Z.A., Chandel, A., and King, C.S. (2023). Pulmonary Hypertension in Interstitial Lung Disease: Updates in Disease, Diagnosis, and Therapeutics. Cells, 12.","DOI":"10.3390\/cells12192394"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ccm.2013.08.004","article-title":"Pulmonary Hypertension Due to Lung Disease and\/or Hypoxia","volume":"34","author":"Nathan","year":"2013","journal-title":"Clin. Chest Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e009047","DOI":"10.1161\/CIRCIMAGING.119.009047","article-title":"Validation of the Tricuspid Annular Plane Systolic Excursion\/Systolic Pulmonary Artery Pressure Ratio for the Assessment of Right Ventricular-Arterial Coupling in Severe Pulmonary Hypertension","volume":"12","author":"Tello","year":"2019","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e70004","DOI":"10.1002\/pul2.70004","article-title":"Non-invasive Surrogates for Right Ventricular-Pulmonary Arterial Coupling: A Systematic Review and Meta-Analysis","volume":"14","author":"Golbin","year":"2024","journal-title":"Pulm. Circ."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e12310","DOI":"10.1002\/pul2.12310","article-title":"Pulmonary Hypertension in the Setting of Interstitial Lung Disease: Approach to Management and Treatment. A Consensus Statement from the Pulmonary Vascular Research Institute\u2019s Innovative Drug Development Initiative\u2014Group 3 Pulmonary Hypertension","volume":"14","author":"Shlobin","year":"2024","journal-title":"Pulm. Circ."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2400172","DOI":"10.1183\/13993003.00172-2024","article-title":"Inhaled Treprostinil in Pulmonary Hypertension Associated with COPD: PERFECT Study Results","volume":"63","author":"Nathan","year":"2024","journal-title":"Eur. Respir. J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"D109","DOI":"10.1016\/j.jacc.2013.10.036","article-title":"Pulmonary Hypertension in Chronic Lung Diseases","volume":"62","author":"Seeger","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/thoraxjnl-2013-204150","article-title":"Changes in Right Heart Haemodynamics and Echocardiographic Function in an Advanced Phenotype of Pulmonary Hypertension and Right Heart Dysfunction Associated with Pulmonary Fibrosis","volume":"69","author":"Saggar","year":"2014","journal-title":"Thorax"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","article-title":"Pulmonary Arterial Hypertension in France: Results from a National Registry","volume":"173","author":"Humbert","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman, D.A., Schwarz, M., Anstrom, K.J., Collard, H.R., Flaherty, K.R., and Hunninghake, G.W. (2010). A Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary Fibrosis. N. Engl. J. Med., 363, 620\u2013628.","DOI":"10.1056\/NEJMoa1002110"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1164\/rccm.200705-732OC","article-title":"BUILD-1: A Randomized Placebo-Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis","volume":"177","author":"King","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1164\/rccm.201011-1874OC","article-title":"BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis","volume":"184","author":"King","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e12430","DOI":"10.1002\/pul2.12430","article-title":"COPD Associated Pulmonary Hypertension: A Post Hoc Analysis of the PERFECT Study","volume":"14","author":"Nathan","year":"2024","journal-title":"Pulm. Circ."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/0003-4819-158-9-201305070-00003","article-title":"Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan","volume":"158","author":"Raghu","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1164\/rccm.201903-0488OC","article-title":"Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE)","volume":"200","author":"Behr","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1164\/rccm.201403-0446OC","article-title":"Bosentan in Pulmonary Hypertension Associated with Fibrotic Idiopathic Interstitial Pneumonia","volume":"190","author":"Corte","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1378\/chest.12-1594","article-title":"Sildenafil Preserves Exercise Capacity in Patients With Idiopathic Pulmonary Fibrosis and Right-Sided Ventricular Dysfunction","volume":"143","author":"Han","year":"2013","journal-title":"Chest"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S2213-2600(19)30250-4","article-title":"Riociguat for Idiopathic Interstitial Pneumonia-Associated Pulmonary Hypertension (RISE-IIP): A Randomised, Placebo-Controlled Phase 2b Study","volume":"7","author":"Nathan","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.healun.2021.02.006","article-title":"Impact of Lung Morphology on Clinical Outcomes with Riociguat in Patients with Pulmonary Hypertension and Idiopathic Interstitial Pneumonia: A Post Hoc Subgroup Analysis of the RISE-IIP Study","volume":"40","author":"Nathan","year":"2021","journal-title":"J. Heart Lung Transplant."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2300944","DOI":"10.1183\/13993003.00944-2023","article-title":"Inhaled Treprostinil for Interstitial Lung Disease-Associated Pulmonary Hypertension: A Silver Lining on a Very Dark Cloud","volume":"61","author":"Cottin","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Puig, P., B\u00e1ez-Guti\u00e9rrez, N., Rodr\u00edguez-Ramallo, H., Abdelkader-Martin, L., and Otero-Candelera, R. (2025). Systematic Evaluation of Subgroup Analyses of Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0318739"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e002116","DOI":"10.1136\/bmjresp-2023-002116","article-title":"Inhaled Treprostinil in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease with Less Severe Haemodynamics: A Post Hoc Analysis of the INCREASE Study","volume":"11","author":"Weatherald","year":"2024","journal-title":"BMJ Open Respir. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1152\/japplphysiol.01104.2010","article-title":"Effects of Inhaled Nitric Oxide at Rest and during Exercise in Idiopathic Pulmonary Fibrosis","volume":"110","author":"Blanco","year":"2011","journal-title":"J. Appl. Physiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.chest.2020.02.016","article-title":"A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis","volume":"158","author":"Nathan","year":"2020","journal-title":"Chest"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.chest.2023.08.023","article-title":"Managing Pulmonary Arterial Hypertension With Cardiopulmonary Comorbidities","volume":"165","author":"Provencher","year":"2024","journal-title":"Chest"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.healun.2009.05.017","article-title":"Treprostinil to Reverse Pulmonary Hypertension Associated with Idiopathic Pulmonary Fibrosis as a Bridge to Single-Lung Transplantation","volume":"28","author":"Saggar","year":"2009","journal-title":"J. Heart Lung Transplant. Off. Publ. Int. Soc. Heart Transplant."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e12178","DOI":"10.1002\/pul2.12178","article-title":"Pulmonary Hypertension in Interstitial Lung Disease: Clinical Trial Design and Endpoints: A Consensus Statement from the Pulmonary Vascular Research Institute\u2019s Innovative Drug Development Initiative\u2014Group 3 Pulmonary Hypertension","volume":"12","author":"Nathan","year":"2022","journal-title":"Pulm. Circ."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6810\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:11:20Z","timestamp":1788343880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":82,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15176810"],"URL":"https:\/\/doi.org\/10.3390\/jcm15176810","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]}}}